Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). This study's objective was to retrospectively identify factors associated with prostate-specific antigen (PSA) response to abiraterone and valid...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433513/
https://ncbi.nlm.nih.gov/pubmed/24458472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt581
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki